Cargando…

Activin B is a novel biomarker for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) diagnosis: a cross sectional study

BACKGROUND: Investigations of activin family proteins as serum biomarkers for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). CFS/ME is a disease with complex, wide-ranging symptoms, featuring persistent fatigue of 6 months or longer, particularly post exertion. No definitive biomarkers...

Descripción completa

Detalles Bibliográficos
Autores principales: Lidbury, Brett A., Kita, Badia, Lewis, Donald P., Hayward, Susan, Ludlow, Helen, Hedger, Mark P., de Kretser, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5353946/
https://www.ncbi.nlm.nih.gov/pubmed/28302133
http://dx.doi.org/10.1186/s12967-017-1161-4
_version_ 1782515232645578752
author Lidbury, Brett A.
Kita, Badia
Lewis, Donald P.
Hayward, Susan
Ludlow, Helen
Hedger, Mark P.
de Kretser, David M.
author_facet Lidbury, Brett A.
Kita, Badia
Lewis, Donald P.
Hayward, Susan
Ludlow, Helen
Hedger, Mark P.
de Kretser, David M.
author_sort Lidbury, Brett A.
collection PubMed
description BACKGROUND: Investigations of activin family proteins as serum biomarkers for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). CFS/ME is a disease with complex, wide-ranging symptoms, featuring persistent fatigue of 6 months or longer, particularly post exertion. No definitive biomarkers are available. METHODS: A cross-sectional, observational study of CFS/ME patients fulfilling the 2003 Canadian Consensus Criteria, in parallel with healthy non-fatigued controls, was conducted. Comparisons with a previously defined activin reference population were also performed. For the total study cohort the age range was 18–65 years with a female: male participant ratio of greater than 3:1. All participants were assessed via a primary care community clinic. Blood samples were collected for pathology testing after physical examination and orthostatic intolerance assessment. Cytokines, activin A, activin B and follistatin were also measured in sera from these samples. All data were compared between the CFS/ME and control cohorts, with the activins and follistatin also compared with previously defined reference intervals. RESULTS: Serum activin B levels for CFS/ME participants were significantly elevated when compared to the study controls, as well as the established reference interval. Serum activin A and follistatin were within their normal ranges. All routine and special pathology markers were within the normal laboratory reference intervals for the total study cohort, with no significant differences detected between CFS/ME and control groups. Also, no significant differences were detected for IL-2, IL-4, IL-6, IL-10, IL-17A, TNF or IFN-gamma. CONCLUSION: Elevated activin B levels together with normal activin A levels identified patients with the diagnostic symptoms of CFS/ME, thus providing a novel serum based test. The activins have multiple physiological roles and capture the diverse array of symptoms experienced by CFS/ME patients.
format Online
Article
Text
id pubmed-5353946
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53539462017-03-22 Activin B is a novel biomarker for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) diagnosis: a cross sectional study Lidbury, Brett A. Kita, Badia Lewis, Donald P. Hayward, Susan Ludlow, Helen Hedger, Mark P. de Kretser, David M. J Transl Med Research BACKGROUND: Investigations of activin family proteins as serum biomarkers for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). CFS/ME is a disease with complex, wide-ranging symptoms, featuring persistent fatigue of 6 months or longer, particularly post exertion. No definitive biomarkers are available. METHODS: A cross-sectional, observational study of CFS/ME patients fulfilling the 2003 Canadian Consensus Criteria, in parallel with healthy non-fatigued controls, was conducted. Comparisons with a previously defined activin reference population were also performed. For the total study cohort the age range was 18–65 years with a female: male participant ratio of greater than 3:1. All participants were assessed via a primary care community clinic. Blood samples were collected for pathology testing after physical examination and orthostatic intolerance assessment. Cytokines, activin A, activin B and follistatin were also measured in sera from these samples. All data were compared between the CFS/ME and control cohorts, with the activins and follistatin also compared with previously defined reference intervals. RESULTS: Serum activin B levels for CFS/ME participants were significantly elevated when compared to the study controls, as well as the established reference interval. Serum activin A and follistatin were within their normal ranges. All routine and special pathology markers were within the normal laboratory reference intervals for the total study cohort, with no significant differences detected between CFS/ME and control groups. Also, no significant differences were detected for IL-2, IL-4, IL-6, IL-10, IL-17A, TNF or IFN-gamma. CONCLUSION: Elevated activin B levels together with normal activin A levels identified patients with the diagnostic symptoms of CFS/ME, thus providing a novel serum based test. The activins have multiple physiological roles and capture the diverse array of symptoms experienced by CFS/ME patients. BioMed Central 2017-03-16 /pmc/articles/PMC5353946/ /pubmed/28302133 http://dx.doi.org/10.1186/s12967-017-1161-4 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Lidbury, Brett A.
Kita, Badia
Lewis, Donald P.
Hayward, Susan
Ludlow, Helen
Hedger, Mark P.
de Kretser, David M.
Activin B is a novel biomarker for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) diagnosis: a cross sectional study
title Activin B is a novel biomarker for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) diagnosis: a cross sectional study
title_full Activin B is a novel biomarker for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) diagnosis: a cross sectional study
title_fullStr Activin B is a novel biomarker for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) diagnosis: a cross sectional study
title_full_unstemmed Activin B is a novel biomarker for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) diagnosis: a cross sectional study
title_short Activin B is a novel biomarker for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) diagnosis: a cross sectional study
title_sort activin b is a novel biomarker for chronic fatigue syndrome/myalgic encephalomyelitis (cfs/me) diagnosis: a cross sectional study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5353946/
https://www.ncbi.nlm.nih.gov/pubmed/28302133
http://dx.doi.org/10.1186/s12967-017-1161-4
work_keys_str_mv AT lidburybretta activinbisanovelbiomarkerforchronicfatiguesyndromemyalgicencephalomyelitiscfsmediagnosisacrosssectionalstudy
AT kitabadia activinbisanovelbiomarkerforchronicfatiguesyndromemyalgicencephalomyelitiscfsmediagnosisacrosssectionalstudy
AT lewisdonaldp activinbisanovelbiomarkerforchronicfatiguesyndromemyalgicencephalomyelitiscfsmediagnosisacrosssectionalstudy
AT haywardsusan activinbisanovelbiomarkerforchronicfatiguesyndromemyalgicencephalomyelitiscfsmediagnosisacrosssectionalstudy
AT ludlowhelen activinbisanovelbiomarkerforchronicfatiguesyndromemyalgicencephalomyelitiscfsmediagnosisacrosssectionalstudy
AT hedgermarkp activinbisanovelbiomarkerforchronicfatiguesyndromemyalgicencephalomyelitiscfsmediagnosisacrosssectionalstudy
AT dekretserdavidm activinbisanovelbiomarkerforchronicfatiguesyndromemyalgicencephalomyelitiscfsmediagnosisacrosssectionalstudy